Polaryx Therapeutics Reports Annual Meeting Results; Directors Elected

What Happened Polaryx Therapeutics, Inc. filed an 8‑K on Sept. 14, 2026 reporting the results of its Annual Meeting of Stockholders held on Sept. 10, 2026. Stockholders elected the company’s two Class I director nominees, Alex Yang and Mitchel Berger, each to serve until the 2029 annual meeting. Stockholders also ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.

Key Details

• Alex Yang: 30,072,137 votes for; 332 withheld; 472,610 broker non‑votes.
• Mitchel Berger: 30,072,137 votes for; 332 withheld; 472,610 broker non‑votes.
• Grant Thornton LLP ratified as auditor: 30,510,106 votes for; 34,973 against; 0 abstentions; no broker non‑votes for this matter.
• The proxy statement referenced in the filing was previously filed with the SEC on July 28, 2026.

Why It Matters Director elections and auditor ratification are routine but material governance outcomes that confirm who will oversee corporate strategy and financial reporting. Investors can note the strong support for the nominees and for Grant Thornton LLP as auditor; the presence of broker non‑votes on the director items indicates some shares were not voted by brokers on those matters. These results do not provide new financial guidance or operating updates, but they affect board composition and the firm responsible for auditing the company’s 2026 financial statements.